

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 9, 2021**

**Taysha Gene Therapies, Inc.**

(Exact name of registrant as specified in its Charter)

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-39536**  
(Commission  
File Number)

**84-3199512**  
(IRS Employer  
Identification No.)

**2280 Inwood Road**  
**Dallas, Texas**  
(Address of Principal Executive Offices)

**75235**  
(Zip Code)

**(214) 612-0000**  
(Registrant's Telephone Number, Including Area Code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.00001 par value	TSHA	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

**Item 8.01 Other Events.**

On March 9, 2021, Taysha Gene Therapies, Inc. (the “Company”) issued a press release entitled “Taysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Genes for an AAV Gene Therapy for the Treatment of Neurodevelopmental Disorders.” The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit No.	Description
99.1	<a href="#">Press release, dated March 9, 2021.</a>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: March 9, 2021

**Taysha Gene Therapies, Inc.**

By: /s/ Kamran Alam

Kamran Alam

Chief Financial Officer



**Taysha Gene Therapies Announces Collaboration to Advance Next-Generation Mini-Gene Payloads for an AAV Gene Therapy for the Treatment of Neurodevelopmental Disorders**

*Taysha to have an exclusive option on new payloads, constructs, and intellectual property arising from research conducted under the agreement*

*Agreement leverages Taysha's existing partnership with UT Southwestern Gene Therapy Program to develop new constructs incorporating novel mini-gene payloads*

**Dallas – March 9, 2021** - Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced a multi-year collaboration to advance next-generation mini-gene payloads for AAV gene therapies for the treatment of neurodevelopmental disorders. Taysha will have an exclusive option on new payloads, constructs, and intellectual property associated with, and arising from, the research conducted under this agreement.

The collaboration with Yong-Hui Jiang, MD, Ph.D., Professor and Chief of Medical Genetics at Yale University, follows the previously announced collaborations with Cleveland Clinic and UT Southwestern Gene Therapy Program (UTSW) to support the creation of a novel next-generation mini-gene platform designed to overcome key challenges in gene therapy. Under the terms of this most recent agreement, a team of researchers from Yale University will create mini-gene payloads designed to treat neurodevelopmental disorders including intellectual disability. UTSW will produce viral vector constructs that incorporate the mini-gene payloads and evaluate the constructs in *in vivo* and *in vitro* efficacy models.

“Our collaboration with Yale is a key addition to our established partnerships with Cleveland Clinic and UTSW, designed to advance our breakthrough next-generation mini-gene platform and to potentially expand the range of genetic diseases that can be treated by AAV-based gene therapy,” said Suyash Prasad, MBBS, M.Sc., MRCP, MRCPC, FFPM, Chief Medical Officer and Head of Research and Development of Taysha. “We look forward to harnessing each partner’s unique capabilities and expertise to better address the challenge of vector capacity and believe our collective efforts may allow significant advancement in the field of gene therapy.”

#### **About Taysha Gene Therapies**

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at [www.tayshagtx.com](http://www.tayshagtx.com).



## **Forward-Looking Statements**

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” “intends,” “projects,” and “future” or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning or implying the potential of our collaborations with Yale University, the Cleveland Clinic and UTSW, the potential of our product candidates to positively impact quality of life and alter the course of disease in the patients we seek to treat, our research, development and regulatory plans for our product candidates, the potential for these product candidates to receive regulatory approval from the FDA or equivalent foreign regulatory agencies, and whether, if approved, these product candidates will be successfully distributed and marketed. Forward-looking statements are based on management’s current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding our business are described in detail in our Securities and Exchange Commission (“SEC”) filings, including in our Annual Report on Form 10-K for the full-year ended December 31, 2020, which is available on the SEC’s website at [www.sec.gov](http://www.sec.gov). Additional information will be made available in other filings that we make from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. These forward-looking statements speak only as of the date hereof, and we disclaim any obligation to update these statements except as may be required by law.

## **Company Contact:**

Kimberly Lee, D.O.  
SVP, Corporate Communications and Investor Relations  
Taysha Gene Therapies  
[klee@tayshagtx.com](mailto:klee@tayshagtx.com)

## **Media Contact:**

Carolyn Hawley  
Canale Communications  
[carolyn.hawley@canalecomm.com](mailto:carolyn.hawley@canalecomm.com)